MDACC Study No:2012-0697 ( NCT No: NCT01751425)
Title:Phase I-II Study of Ruxolitinib (INCB18424) for Patients with Chronic Myeloid Leukemia (CML) with Minimal Residual Disease While on Therapy with Tyrosine Kinase Inhibitors
Principal Investigator:Jorge Cortes
Treatment Agent:Ruxolitinib
Study Status:Open
Study Description:Unavailable
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I/Phase II
Treatment Agents:Ruxolitinib
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:Incyte Corporation
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jorge Cortes
For Clinical Trial Enrollment:713-794-5783
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults